îæ€çŽ¢
îæ€çŽ¢
î
Urogen Pharma Ltd
URGNîãŠã©ãããªã¹ãã«è¿œå
38.240USD
-2.850-6.94%
çµå€Â 07-31 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
1.86Bæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
詳现æ å ± Urogen Pharma Ltd äŒæ¥å
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Urogen Pharma Ltdã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãURGN
äŒç€ŸåUrogen Pharma Ltd
äžå Žæ¥May 04, 2017
æé«çµå¶è²¬ä»»è
ãCEOãBarrett (Elizabeth A)
åŸæ¥å¡æ°235
蚌åžçš®é¡Ordinary Share
決ç®ææ«May 04
æ¬ç€Ÿæåšå°9 Ha'ta'asiya St
éœåžRA'ANANA
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœIsrael
éµäŸ¿çªå·4365007
é»è©±çªå·97297707601
ãŠã§ããµã€ãhttps://www.urogen.com/
äŒæ¥ã³ãŒãURGN
äžå Žæ¥May 04, 2017
æé«çµå¶è²¬ä»»è
ãCEOãBarrett (Elizabeth A)
Urogen Pharma Ltdã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
51.33K
--
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
51.33K
--
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
2.00K
--
Dr. Stuart Holden, M.D.
Dr. Stuart Holden, M.D.
Independent Director
Independent Director
--
--
ãããã質å
Urogen Pharma Ltdã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îUrogen Pharma Ltdã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ããDr. Arie S. Belldegrun, M.D.
Urogen Pharma LtdïŒURGNïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2026Q1æç¹ã§ãUrogen Pharma Ltdã®æ ªåŒãä¿æããŠããæ©é¢ã¯349瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ46.29Mã§ãå
šäœã®95.00%ãå ããŠããŸãã2025Q4ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯-15691017.00å¢å ããŠããŸãã
Urogen Pharma Ltdã®æ倧ã®åçæºã¯äœã§ããïŒ
î2026Q1ã«ãããŠãJelmytoéšéãUrogen Pharma Ltdã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯93.99Mã§ãå
šåçã®85.61%ãå ããŠããŸãã